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ABSTRACT 
Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. 
Treatment options are limited and the mechanisms underlying its aggressiveness are 
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poorly understood. Intermittent hypoxia (IH) causes oxidative stress and is emerging 
as important regulator of tumor metastasis. Vessels in IBC tumors have been shown 
to be immature, which is a primary cause of IH. We therefore investigated the 
relevance of IH for the modulation of gene expression in IBC cells in order to assess 
IH as potential regulator of IBC aggressiveness. Gene array analysis of IBC cells 
following chronic IH (45-60 days) demonstrated increased expression of pro-
metastatic genes of the extracellular matrix, such as tenascin-C (TNC; an essential 
factor of the metastatic niche) and matrix metalloproteinase 9 (MMP9), and of pro-
inflammatory processes, such as cyclooxygenase-2 (COX-2). Investigating the 
oxidative stress-dependent regulation of TNC, we found a gradual sensitivity on 
mRNA and protein levels. Oxidative stress activated NF-E2-related factor 2 (Nrf2), c-
Jun N-terminal kinase (JNK), c-Jun and nuclear factor B (NF-B), but TNC 
upregulation was only dependent on NF-B activation. Pharmacological inhibition of 
inhibitor of NF-B  (IB) phosphorylation as well as overexpression of IB 
prevented TNC, MMP9 and COX-2 induction, whereas the pro-inflammatory cytokine 
interleukin-1 (IL-1) increased their expression levels. Analysis of the gene array 
data showed NF-B binding sites for 64% of all upregulated genes, linking NF-B 
with IH-dependent regulation of pro-metastatic gene expression in IBC cells. Our 
results provide a first link between intermittent hypoxia and pro-metastatic gene 
expression in IBC cells, revealing a putative novel mechanism for the high metastatic 
potential of IBC. 
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INTRODUCTION 
Inflammatory breast cancer (IBC) is the most aggressive and most lethal form of 
primary breast cancer. While IBC is estimated to account for up to 5% of all breast 
cancer cases, it leads to approx. 8-10% of all breast cancer-related deaths [1-3]. IBC 
presents with a diffuse tumor formation and is highly metastatic with lymph node 
metastases being found in almost all and distant metastases in 30% of patients, 
respectively, at the time of diagnosis [2]. Treatment of IBC patients has proven to be 
challenging due to its rapid progression and aggressive nature [2,4]. The 
mechanisms underlying the aggressiveness of IBC are poorly understood, impeding 
the development of targeted therapy [2,5]. In addition, the investigation of molecular 
signaling pathways leading to the development of the aggressive phenotype of IBC is 
difficult, because of a limited availability of tumor material and with only two primary 
tumor-derived cell lines existing [5,6]. 
 Tumors frequently outgrow their blood oxygen supply, leading to insufficient 
oxygen levels (hypoxia) and subsequent induction of angiogenesis [7]. The induced 
tumor vessels are often not properly developed, leading to fluctuations of blood and 
hence oxygen supply [8]. Oxygen levels in solid tumors are therefore dynamic, with 
repeated cycles of hypoxia and reoxygenation, called chronic intermittent hypoxia 
(CIH) or cycling hypoxia [8]. CIH cycles can occur in short (minutes to hours) and 
long (hours to days) intervals [8,9]. High frequency cycles can be caused by 
differences in red blood cell flux through perturbations of the microvessel diameter, 
while slow frequency cycles can occur through restructuring of tumor microvessels, 
which has been observed in tumors to occur on a daily basis [8]. CIH, although not 
directly assessed yet in IBC, likely also occurs in IBC tumors, because analysis of 
IBC tumor tissue showed hypoxia-dependent gene expression (carbonic anhydrase 
IX (CA9) induction) in 50% of the tumors and overall a higher microvessel density 
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than in other breast cancer forms [4,10,11]. Moreover, approx. 90% of IBC tumor 
blood vessels are not fully developed [12]. Of note, CIH leads to enhanced tumor 
microvessel density, which could present a link to the increased microvessel density 
in IBC tumors [13]. In addition, CIH has been shown to be a stronger inducer of 
cancer metastases than continuous hypoxia [14,15]. However, the role of CIH in IBC 
progression and aggressiveness is unclear. 
The median oxygen partial pressure of a tumor is 30-38 mmHg (corresponding 
to 4-5% oxygen content in the gas phase), but fluctuating local oxygen gradients lead 
to a varying oxygenation between different tumor areas and cells, and the actual 
oxygen partial pressure experienced by each tumor cell depends on its proximity to 
vessels, local blood oxygenation, and on the oxygen consumption of surrounding 
cells, including tumor stroma and infiltrating immune cells [16,17]. Because it is not 
possible to accurately recreate such a complex situation in vitro, two clearly distinct 
normoxic and hypoxic oxygen levels were used for the investigations of the effect of 
CIH on IBC cells (normoxia: 20.9% O2, hypoxia: 0.2% O2). 
CIH is a major source of oxidative stress due to reactive oxygen species 
(ROS) generation [8,18,19]. Oxidative stress can affect gene expression through 
regulation of DNA methylation and transcription factor activity [18,20,21]. While the 
mechanism of oxidative stress-dependent regulation of DNA methylation is less 
clear, several transcription factors have been reported to be activated by IH/oxidative 
stress, including NF-E2-related factor 2 (Nrf2), hypoxia-inducible factor (HIF), 
activator protein-1 (AP-1) and nuclear factor B (NF-B) [18,21,22]. Nrf2 is the main 
regulator of the cellular antioxidant response [23]. HIF is the master regulator of the 
transcriptional response to hypoxia but its activation by oxidative stress is still highly 
debated [8,24-27]. ROS have been reported to stabilize HIF-1, but HIF-1was not 
affected by ROS in other studies [8,18,19,24,25,27-29]. AP-1 has been linked to the 
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regulation of a wide range of cellular processes, including proliferation, migration and 
inflammation and has been reported to play an important role in tumor cell 
proliferation in the context of oxidative stress [30,31]. NF-B is the master regulator 
of the cellular transcriptional response to inflammation [32,33]. In cancer cells, NF-B 
activity can increase the expression of genes that promote proliferation, 
invasiveness, metastasis and apoptosis [34,35]. 
 The extracellular matrix (ECM) plays an important role in the development and 
progression of breast cancer [36]. For example, the matrix metalloproteinases 2 and 
9 (MMP2, MMP9) and a disintegrin and metalloproteinase 19 (ADAM19) are 
remodeling enzymes of the ECM and play a major part in the development of tumor 
metastasis and invasion [36,37]. Tenascin-C (TNC), a large hexameric ECM 
glycoprotein, is highly expressed during development, almost absent during postnatal 
live, but re-expressed in case of injury and in the onset of tumorigenesis [38]. 
Increased expression of TNC has been related to poor prognosis, local and distant 
recurrence in breast carcinomas and metastasis formation [36,39]. Of note, TNC has 
been shown to be an essential factor of the metastatic niche [36]. 
 In the current study, we investigated the impact of IH and the resulting 
oxidative stress on transcriptional regulation in IBC cells. We provide evidence that 
CIH and oxidative stress are important regulators of pro-metastatic gene expression 
specifically in IBC cells. Investigation of the underlying mechanism of upregulated 
TNC gene expression showed that it is dependent on NF-activation but not on 
DNA methylation, Nrf2, AP-1 and HIF. Furthermore, 64% of all CIH-upregulated pro-
metastatic genes can be regulated by NF- These data provide a mechanistic link 
between intermittent hypoxia and pro-metastatic gene expression in IBC cells, 
contributing novel insights into the regulation of IBC aggressiveness.  
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MATERIAL AND METHODS 
Reagents 
Tert-butylhydroquinone (30 M) (tBHQ; Sigma-Aldrich, St Louis, MO, USA), dimethyl 
fumarate (40 M) (DMF; Sigma-Aldrich), BAY11-7082 (12.5 M, 25 M) (Selleck, 
Houston, TX, USA), H2O2 (100 M, 500 M) (Sigma-Aldrich) and 2',7'-
dichlorodihydrofluorescein diacetate (10 M) (H2DCFDA; Invitrogen, Thermo Fischer 
Scientific, Waltham, MA, USA) were dissolved in ethanol. L-Sulforaphane (10 M) 
(SFN; Sigma-Aldrich) and SP600125 (10 M, 20 M) (Selleck) were dissolved in 
DMSO and N-acetyl-L-cysteine (3 mM, 20 mM) (NAC; Sigma-Aldrich) was dissolved 
in H2O. IL-1 (2 ng/ml) (R&D Systems, Minneapolis, MN, USA) was dissolved in 
0.1% BSA in PBS. 
 
Cell culture and treatments 
The human triple-negative IBC breast cancer cell line SUM149PT was kindly 
provided by Rachael Natrajan (London, UK) and was used for all subsequent cell 
culture experiments if not otherwise indicated. SUM149PT cells were cultured in 
equal parts of high-glucose DMEM (Sigma-Aldrich) and Ham's F-12 Nutrient Mixture 
(Gibco, Thermo Fischer Scientific, Waltham, MA, USA), supplemented with 5% heat-
inactivated fetal bovine serum (FBS), 1 g/ml hydrocortisone (Sigma-Aldrich), 5 
g/ml human insulin (Sigma-Aldrich), 100 U/ml penicillin and 100 g/ml streptomycin 
(Sigma-Aldrich). Reagents were diluted to the required concentration in the 
appropriate medium without FBS and supplements. Cells were seeded at 70-80% 
confluency. BAY11-7082, SP600125 and N-acetyl-L-cysteine were added to the cells 
1 h before addition of tBHQ. Normoxic experiments were performed in a humidified 
atmosphere containing 20.9% O2 (131.8 mmHg) and 5% CO2 (35.7 mmHg) in a cell 
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culture incubator (Binder, Tuttlingen, Germany). Hypoxic experiments were carried 
out in a humidified atmosphere containing 0.2% O2 (1.26 mmHg) and 5% CO2 in a 
gas-controlled glove box (Invivo2 400, Baker Ruskinn, Bridgend, UK) as previously 
described [40]. 
 
mRNA analysis and data deposition 
The RNeasy mini kit (Qiagen, Hilden, Germany) was used for total RNA extraction for 
the Affymetrix gene array analysis according to manufacturer’s protocol. Affymetrix 
Human Gene 2.1 ST strip arrays were used to analyze transcript levels of one 
biological replicate of untreated cells and of cells cultured for 45 days in CIH. The 
data were deposited in Gene Expression Omnibus (GEO; 
http://www.ncbi.nlm.nih.gov/geo/) and are accessible through the ID GSE81416 
(reviewers access: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=ihgnacgezfkxlil&acc=GSE8141
6). For validation of the Affymetrix gene array results, three biological replicates of 
untreated cells and cells that were cultured for 45-60 days in normoxia or CIH 
conditions were analyzed by RT-qPCR as previously described [41]. The relative 
mRNA expression was calculated using the Ct formula. U6 snRNA served as 
control gene and values were normalized to the average values of normoxic controls. 
For all further experiments, total cellular RNA was extracted as previously described 
[42]. Primer sequences were listed in Supplementary Table S3. mRNA copy numbers 
were calculated by comparison with serial dilutions of a calibrated standard, 
calculated relative to U6 snRNA levels and normalized to the starting time point if not 
otherwise indicated. 
 
Bioinformatic analysis of Affymetrix gene expression array 
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For the analysis of the Affymetrix gene array results, protein coding genes, as listed 
in the National Center for Biotechnology Information (NCBI) Reference Sequence 
(RefSeq) database, with  4-fold increased transcript levels were used for 
bioinformatic analyses with MetaCore (https://portal.genego.com/) from Thomson 
Reuters. Enrichment analysis according to standard settings of the software was 
performed to rank the most relevant cellular processes. p values were calculated as 
–log10. To analyze literature-based transcriptional regulations, the “build network” 
option with the algorithm for “transcription regulation” was applied. In order to link 
single genes to the matrisome, analysis was performed via the matrisome project for 
each upregulated gene (http://matrisomeproject.mit.edu/proteins/) [43]. For detection 
of conserved transcription factor binding sites (TFBS), the web-based software 
oPOSSUM version 3 (http://opossum.cisreg.ca/oPOSSUM3/) was used [44-46]. The 
matrices of TFBS profiles included in oPOSSUM-3 were obtained from the 2010 
release of the JASPAR database (http://jaspar.genereg.net) [47]. For detection of 
TFBS in the TNC promoter, the UCSC genome browser (http://genome.ucsc.edu/) 
was searched with the genome assembly released in February 2009 [48]. Further, 
the Swissregulon (http://swissregulon.unibas.ch/fcgi/sr) and the JASPAR databases 
were searched [49]. 
 
Protein detection and quantification 
Proteins were extracted from cells using 0.4 M NaCl, 1% Nonidet P-40, 10 mM Tris-
HCl (pH 8.0), 1 mM EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 
mM sodium-orthovanadate and protease inhibitor cocktail (P2714, Sigma-Aldrich). 
Equal amounts of protein were separated by SDS-PAGE, transferred to nitrocellulose 
membranes and detected with antibodies against HIF-1 (BD Transduction 
Laboratories, Allschwil, Switzerland); -actin (Sigma-Aldrich); SMC1 (Abcam, 
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Cambridge, UK); tenascin-C (H-300, Santa Cruz Biotechnology, Dallas, TX, USA); 
Nrf2 (H-300, Santa Cruz Biotechnology); -tubulin (Sigma-Aldrich); c-Jun, phospho-
c-Jun(Ser63), phospho-c-Jun(Ser73), IB , phospho-IB, COX-2, MMP9 (all Cell 
Signaling Technologies, Danvers, MA, USA); and Nrf3 [50]. Detection of primary 
antibodies and recording of chemiluminescence were carried out as previously 
described [40]. Quantification of immunoblotting signals was performed using ImageJ 
1.48v (http://imagej.nih.gov/ij) or as previously described [40]. Values were 
normalized to the respective loading control and to the average values of normoxic 
controls if not otherwise indicated. 
 
Detection of secreted TNC by enzyme-linked immunosorbent assay (ELISA) 
SUM149PT cell treatments were performed in equal volumes of medium and medium 
was collected following 24 h of tBHQ treatment and frozen at -20°C until analysis. 
Secreted tenascin-C was detected with the human Tenascin-C Large (FNIII-C) 
ELISA Kit (IBL, Japan) as per manufacturer's description. 
 
siRNAs and plasmids 
For siRNA experiments, cells were seeded to reach 60% confluency on the day of 
transfection. Nrf2 siRNA (ON-TARGET plus Human NFE2L2 siRNA, SMART pool), 
Nrf3 siRNA (ON-TARGET plus Human NFE2L3 siRNA, SMART pool), c-Jun siRNA 
(ON-TARGET plus Human JUN siRNA, SMART pool) and non-target siRNA (ON-
TARGET plus Non-targeting Pool) were purchased from Dharmacon (GE Healthcare, 
Lafayette, CO, USA) and transfected using Lipofectamine 2000 (Invitrogen) and Opti-
MEM (GIBCO) according to manufacturers' protocols. For plasmid transfections, cells 
were seeded to reach 70% confluency on the day of transfection. NC16 pcDNA3.1 
FLAG Nrf2 was a gift from Randall Moon (Addgene plasmid # 36971) [51], pCMV4-3 
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HA/IB was a gift from Warner Greene (Addgene plasmid # 21985) [52] and 
pcDNA3.1-hNFE2L3 has previously been published [50]. Treatments were performed 
after 24 h of transfection. 
 
DCF assay 
SUM149PT cells were seeded in 96-well plates and incubated with 10 M H2DCFDA 
for 30 min in the dark. Subsequently, specific treatments were performed and 
fluorescence was measured using a 96-well fluorescence photometer (Infinite 
200Pro, Tecan, Männedorf, Switzerland). For combined treatments with tBHQ and 
NAC, cells were pretreated for 1 h with NAC. Results were calculated as increase in 
fluorescence per well ((Ftx – Ft0) / Ft0*100), where Ftx = fluorescence at a certain 
time point and Ft0 = fluorescence at 0 min [53]. For hypoxia-reoxygenation 
experiments, 96-well plates were incubated for 24 h in 0.2% oxygen. Cells were 
incubated with H2DCFDA inside the hypoxia workstation and fluorescence 
measurements were performed immediately thereafter. For measurements during 
hypoxic incubation, plates were sealed at measurement time points with oxygen 
impenetrable foils (Brand GMBH+ CO KG, Wertheim, Germany) within the hypoxia 
workstation and measurements were performed as described. 
 
Statistical analyses 
If not otherwise indicated, results are presented as mean values ± standard error of 
the mean (SEM) of at least three independent experiments. Statistical analyses were 
performed using Student's t-test and one-way ANOVA or two-way ANOVA where 
appropriate. P-values <0.05 were considered statistically significant. 
  
12 
 
RESULTS 
Chronic intermittent hypoxia increases pro-metastatic gene expression in 
inflammatory breast cancer cells. 
In order to investigate the impact of CIH on IBC, the primary tumor-derived IBC cell 
line SUM149PT was cultured for 45 days in CIH conditions (15 cycles of 
hypoxia/reoxygenation; Fig. 1A) and gene expression was assessed by whole 
genome microarray hybridization. Using a four-fold difference relative to control as 
threshold for relevant gene regulation, 37 genes were identified to be upregulated 
and 51 genes to be downregulated in response to CIH. Analysis of associations of 
the upregulated genes with cellular processes via MetaCore 
(https://portal.genego.com/) showed that these genes are primarily involved in the 
regulation of the ECM (Fig. 1B). 13 out of the 37 upregulated genes were linked to 
the “matrisome”, which is composed of ECM and ECM-associated proteins 
(Supplementary Table S1) [43]. A second relevant process associated with CIH-
upregulated gene expression was inflammation (Fig. 1B). 
The CIH experiment was repeated to validate the expression levels of 10 out 
of the 37 upregulated genes. TNC, MMP2, MMP9 and ADAM19 were chosen 
because these proteins are important components and remodeling enzymes of the 
ECM, and since they have previously been shown to play a major role in tumor 
invasion and metastasis [36,37]. Triggering receptor expressed on myeloid cells 
(TREM1), interleukin-1 (IL1A) and cyclooxygenase-2 (COX-2; gene name: PTGS2, 
prostaglandin G/H synthase 2) have been linked before to inflammatory processes, 
and COX-2 has been associated with a more aggressive breast cancer phenotype 
[2]. NF-E2-related factor 3 (Nrf3, gene name: NFE2L3) is a homolog of the 
transcription factor Nrf2 and might be part of the oxidative stress response [54]. Src 
homology 2 domain containing family member 4 (SHC4) plays a critical role in 
13 
 
migration of metastatic melanomas and potentially in the response to oxidative 
stress-induced DNA damage; and a SNP in X-ray repair complementing defective 
repair in Chinese hamster cells 2 (XRCC2), which is involved in homologous 
recombination DNA repair, was linked to spontaneous breast cancer development 
[55-57]. We analyzed the expression pattern of these genes in response to hypoxia, 
reoxygenation (both part of cycle 1 of the CIH experiment; Fig. 1A) and CIH (15-20 
cycles; Fig. 1A). All genes except MMP9 demonstrated a significant upregulation 
following CIH (Fig. 2A). But also MMP9 showed an upregulation in response to CIH 
in all three independent experiments, only with a higher degree of variability. To 
analyze the expression patterns further, we directly compared the observed induction 
factors of the different treatments to each other and identified three differentially 
regulated groups (Fig. 2B). Group I showed only upregulated gene expression in 
response to CIH, while group II genes were already increased in response to a single 
reoxygenation stimulus (Fig. 2B), and group III was upregulated by all three 
treatments (Fig. 2B). These findings indicate that some of these genes are only 
sensitive to a higher oxidative stress such as CIH (group I), while others are already 
upregulated by a single reoxygenation event (group II). In group III, we most likely 
observed overlapping regulation between hypoxia and the oxidative stress response. 
Of note, no increase in prototypical HIF target genes (e.g. CA9 or glycolytic 
enzymes) was observed in the gene array following CIH, indicating that HIF-
dependent gene expression was not present in our CIH conditions at the time of 
analysis. In order to determine if CIH also led to increased protein levels, we 
determined TNC protein expression following the three different treatments. TNC 
protein expression followed the same pattern as its mRNA, with no upregulation in 
response to hypoxia or a single reoxygenation event but with a significant increase 
following 15 and 20 cycles of CIH (Fig. 2C, D). 
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Overall, these results demonstrate that CIH increases pro-metastatic gene 
expression in IBC cells. In addition, we identified three distinct groups of regulated 
genes, indicating a differential sensitivity to oxidative stress and hypoxia among the 
investigated genes. The observed changes on mRNA levels translated into protein 
expression, indicating functional relevance. 
 
Tenascin-C expression demonstrates a gradual sensitivity to increasing 
oxidative stress levels specifically in IBC cells 
We next investigated the underlying mechanism of the CIH-dependent increase in 
pro-metastatic gene expression. We focused on TNC expression because its mRNA 
and protein levels were specifically upregulated in response to CIH but not to 
hypoxia, demonstrating that its regulation depends on repeated reoxygenation events 
(Fig. 2). Furthermore, TNC has been linked to breast cancer development, it plays a 
major role in tumor progression and metastasis, and it has been shown to be an 
essential factor of the metastatic niche [36]. Because CIH is a well-established 
oxidative stress inducer and likely leads to a more severe oxidative stress than a 
single reoxygenation event [8,18,58], we aimed to investigate the effect of increasing 
oxidative stress conditions on TNC-dependent gene expression. First, we compared 
the potential of different stimuli, a single hypoxia/reoxygenation phase, hydrogen 
peroxide (H2O2) and tBHQ, to induce oxidative stress in SUM149PT cells using the 
DCF assay (Fig. 3A-C). Within cells, tert-butylhydroquinone (tBHQ) autooxidizes via 
an intermediate step as semiquinone to tert-butylquinone in an oxygen-dependent 
manner, forming two oxygen radicals per each tBHQ molecule [59]. 
Hypoxia/reoxygenation led to a short but significant increase in DCF fluorescence at 
early time points (0.5 h) (Fig. 3A), while 100 M H2O2 led to a prolonged, plateauing 
increase in fluorescence over 4 h (Fig. 3B). 30 M tBHQ induced a steady increase 
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in fluorescence over 4 h and the observed signal was up to 4-fold higher than with 
single hypoxia/reoxygenation or H2O2 (Fig. 3A-C). Hypoxia did not increase DCF 
fluorescence, indicating that the reoxygenation phase following hypoxic incubation is 
necessary for a detectable increase in ROS levels (Supplementary Fig. 1A & B). This 
established the following order of ROS induction by these treatments: tBHQ (30 M) 
> H2O2 (100 M) > single reoxygenation. 
DCF assay analysis of SUM149PT cells following the CIH experiment showed 
that there was no further increased fluorescence upon hypoxia/reoxygenation in 
comparison to cells that had not been cultivated in CIH (Supplementary Fig. S1C). 
This indicates that long-term cultivation of SUM149PT cells in CIH does not change 
the intrinsic cellular ROS production in response to reoxygenation. 
Next, we investigated the impact of the different ROS sources on TNC mRNA 
and protein expression. Hypoxia/reoxygenation led to a significant but short and 
transient increase in TNC mRNA levels at 2 and 4 h (Fig. 3D), while H2O2 
significantly induced TNC mRNA at 4-8 h (Fig. 3E) and tBHQ at 9 h and 24 h (Fig. 
3F), with 5 to 9-fold higher TNC mRNA levels following tBHQ treatment compared to 
the other treatments (Fig. 3D-F). On the protein level, hypoxia/reoxygenation neither 
induced TNC (Fig. 3G) nor activated the positive control for oxidative stress, the 
redox-sensitive transcription factor Nrf2 (data not shown). CA9 mRNA levels and 
HIF-1 protein levels were used as positive controls for hypoxia (Fig. 3G, 
Supplementary Fig. S1D). In turn, H2O2 increased TNC protein levels significantly 
after 6 h (Fig. 3H). Nrf2 protein was stabilized and its target gene heme oxygenase 1 
(HO-1) was elevated in response to H2O2 treatment (Fig. 3H, Supplementary Fig. 
S1E). tBHQ treatment led to a strongly increased protein expression after 9 h and 24 
h (Fig. 3I). Nrf2 protein levels and HO-1 mRNA were also elevated by tBHQ (Fig. 3I, 
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Supplementary Fig. S1F). Of note, the observed differences of activated Nrf2 protein 
levels between the treatments are in agreement with the differences of ROS 
measured by the DCF assay (tBHQ > H2O2 > single reoxygenation), further 
supporting a differential ROS induction between the treatments (Fig. 3A-C, G-I). 
tBHQ treatment also led to an increased secretion of TNC protein (Fig. 3J), further 
indicating the functional relevance of the observed TNC regulation. 
In order to test if the observed ROS-dependent regulation of TNC also occurs 
in triple-negative non-IBC breast cancer cells, we investigated the effect of tBHQ 
treatment on TNC expression in the MDA-MB-231 and MDA-MB-468 cell lines. tBHQ 
treatment led to a significant increase in Nrf2 protein and HO-1 mRNA levels in MDA-
MB-231 cells, indicating effective ROS induction, but did not increase TNC mRNA or 
protein levels (Supplementary Fig. S2A-C). In MDA-MB-468 cells, tBHQ treatment 
also led to increased Nrf2 protein levels but did not upregulate TNC protein 
(Supplementary Fig. S2D). These data indicate that the observed ROS-dependent 
regulation of TNC is specific to IBC cells. 
 Overall, TNC expression shows a gradual sensitivity to ROS levels specifically 
in inflammatory breast cancer cells, indicating that CIH increases TNC expression 
through increasing oxidative stress. 
 
Antioxidant treatment prevents oxidative stress-mediated TNC induction 
We next sought to determine if the observed TNC induction was directly dependent 
on ROS. SUM149PT cells were pre-treated with the antioxidant NAC for 1 h followed 
by the addition of tBHQ. NAC prevented tBHQ-mediated ROS production (Fig. 4A) as 
well as tBHQ-mediated upregulation of TNC protein levels (Fig. 4B). These results 
demonstrate that regulation of TNC expression is directly linked to oxidative stress 
and can be prevented by antioxidant treatment. 
17 
 
 
Oxidative stress-dependent TNC induction is independent of Nrf2 and Nrf3 
DNA methylation is frequently involved in chronic changes of gene expression and 
can be regulated by oxidative stress [20]. Therefore, we first investigated a potential 
impact of CIH on DNA methylation as a molecular mechanism for the regulation of 
TNC expression. Although CpG-rich regions were identified in the TNC promoter and 
in the first untranslated exon of TNC, no difference in methylation following CIH was 
observed in the TNC promoter by methylation-specific PCR (MSP) (Supplementary 
Fig. S3) nor in the TNC promoter or the first untranslated exon of TNC by bisulfite 
sequencing PCR (BSP) (data not shown). 
A main transcription factor activated by oxidative stress is Nrf2 [23]. Nrf2 
protein was stabilized and Nrf2-dependent target genes were increased in 
SUM149PT cells following H2O2 and tBHQ treatment (Fig. 3H, I, Supplementary Fig. 
S1E, F). In addition, in response to CIH we observed elevated Nrf3 mRNA levels 
(Fig. 2A). Nrf3 belongs to the same Cap’n’Collar transcription factor family as Nrf2 
and has also been linked to the cellular antioxidant response [54]. Furthermore, the 
TNC promoter can be regulated by BACH1, a transcriptional suppressor binding 
antioxidant response elements (AREs) (Fig. 5A) [60]. Following oxidative stress, 
BACH1 does not suppress ARE-dependent transcription anymore [60], allowing e.g. 
Nrf2 or Nrf3 to bind instead (Fig. 5A). Therefore, we transiently knocked down Nrf2 
and/or Nrf3 in SUM149PT cells, followed by tBHQ treatment. No significant 
difference in tBHQ-dependent TNC induction was detected with single or combined 
Nrf2 and Nrf3 knockdown (Fig. 5B), while HO-1 induction, a known direct Nrf2 target 
gene, was significantly down-regulated (Fig. 5C) [23]. Interestingly, knockdown of 
Nrf3, which had previously been reported to be capable of both inducing and 
repressing gene transcription [61], increased HO-1 expression, indicating that Nrf3 is 
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a repressor of ROS-induced HO-1 expression (Fig. 5C). Single and combined 
knockdown or overexpression of Nrf2 and Nrf3 showed no major effect on basal TNC 
gene expression (Supplementary Fig. S4). In addition, the effect of two chemical Nrf2 
activators on TNC expression was tested, SFN and DMF. SFN and DMF mediate 
stabilization and nuclear translocation of Nrf2 by modulating the inhibitory protein of 
Nrf2, kelch-like ECH-associated protein 1 (Keap1) [62,63]. SUM149PT cells were 
treated with 10 M SFN and samples were collected for up to 24 h. No change in 
TNC mRNA expression was detected, while the induction of HO-1 6 h after treatment 
demonstrated efficient Nrf2 activation (Fig. 5D). Treatment with 40 M DMF caused 
only a slight elevation in TNC mRNA levels after 24 h, but showed a significant HO-1 
induction from 3 h to 9 h (Fig. 5E). Increased TNC mRNA levels through DMF 
stimulation correlated with increased ROS levels while SFN caused no significant 
ROS production and no elevated TNC mRNA levels (Supplementary Fig. S5). Of 
note, the increase in ROS following DMF treatment was much lower than the ROS 
levels measured after H2O2 treatment and negligible compared to the ROS 
production caused by tBHQ (Fig. 3B, C, Supplementary Fig. S5B). 
Overall, these results demonstrate that oxidative stress-dependent TNC 
induction is independent of Nrf2 and Nrf3. 
 
Oxidative stress-dependent TNC induction is independent of JNK and c-Jun 
activity 
Another transcription factor activated by oxidative stress and IH is AP-1, which is 
regulated by mitogen-activated protein kinase (MAPK) signaling [18,21,30]. AP-1 is a 
dimeric protein that can be composed of several different subunits of which the major 
protein subfamilies are Jun (c-Jun, JunB, JunD) and Fos (c-Fos, FosB, Fra-1, Fra-2) 
[30]. The TNC promoter contains ChIP-based binding sites for AP-1 subunits such as 
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c-Jun (Fig. 5A). tBHQ increased over a time course of 24 h c-Jun phosphorylation on 
serine 63 and 73, which enhances c-Jun transcriptional activity (Fig. 6A) [30]. In 
addition, total c-Jun protein levels were increased (Fig. 6A). c-Jun has been reported 
to be phosphorylated on serine 63 and 73 by the MAPK c-Jun N-terminal kinase 
(JNK) [30]. Therefore, we next investigated if tBHQ-dependent c-Jun phosphorylation 
could be prevented by the JNK inhibitor SP600125. One hour pre-treatment with 
SP600125 blocked tBHQ-dependent c-Jun phosphorylation (Fig. 6B), indicating that 
tBHQ activates the MAPK signaling cascade at the level of or upstream of JNK. 
However, the JNK inhibitor did not prevent tBHQ-mediated TNC induction (Fig. 6C). 
Furthermore, siRNA-mediated knockdown of c-Jun did also not significantly affect 
tBHQ-dependent TNC induction (Fig. 6D). These results show that oxidative stress 
activates MAPK signaling and c-Jun in IBC cells but the oxidative stress-dependent 
increase of TNC is independent of this mechanism. 
 
Oxidative stress-dependent TNC induction is mediated by NF-B. 
A further transcription factor activated by oxidative stress is NF-B, which also has a 
putative binding site in the TNC promoter (Fig. 5A). Hence, we next tested if tBHQ 
can activate NF-B in IBC cells and treated SUM149PT cells with tBHQ over a 24 h 
time course. This led to a time-dependent decrease of inhibitor of NF-B  (IB) 
protein levels (Fig. 7A), demonstrating activation of the NF-B signaling pathway. 
Pre-treatment with BAY11-7082, which prevents phosphorylation and subsequent 
degradation of IB [64], blocked the tBHQ-dependent decrease of IB (Fig. 7B), 
indicating that tBHQ-mediated oxidative stress activates the NF-B signaling 
pathway at the level of or upstream of IB phosphorylation. Inhibitor treatment 1 h 
prior to the tBHQ stimulus abrogated the increase in TNC expression (Fig. 7C), 
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indicating that NF-B regulates oxidative stress-mediated TNC induction. We 
expanded our investigations further to MMP9 and COX-2, which had shown 
increased expression in response to CIH (Fig. 2A, B) and which were upregulated in 
response to tBHQ treatment (Supplementary Fig. S6A). Pre-treatment with BAY11-
7082 abrogated the tBHQ-dependent increase of MMP9 and attenuated tBHQ-
dependent COX-2 upregulation (Fig. 7C). Overexpression of IB also prevented the 
oxidative stress-dependent induction of TNC, MMP9 and partly of COX-2, overall 
confirming their regulation by the NF-B signaling pathway (Fig. 7D). H2O2, which 
induced TNC mRNA and protein expression (Fig. 3E, H), also increased NF-B 
activity in an NF-B dependent luciferase reporter gene assay in SUM149PT cells, 
indicating that the observed ROS-dependent NF-B activity in IBC cells is a general 
consequence of oxidative stress and not specific to the tBHQ stimulus 
(Supplementary Fig. S6B). 
Treatment with the major pro-inflammatory cytokine IL-1, one of the best-
characterized NF-B activating stimuli [64,65], showed a decrease of IB levels at 
30 min and a strong increase in TNC and COX-2 protein levels from 3-24 h and of 
MMP9 from 9-24 h (Fig. 7E). Analysis of breast cancer transcriptomic datasets 
revealed a significant, positive correlation between TNC and nuclear factor B p105 
subunit levels (Supplementary Fig. S7). Together with the previous results, this 
demonstrates that oxidative stress-induced TNC, MMP9 and COX-2 expression is 
regulated by NF-B. Interestingly, when we investigated our CIH gene array results 
for transcription factor binding sites and known regulation by transcription factors 
using oPOSSUM and MetaCore (http://opossum.cisreg.ca/oPOSSUM3/ and 
https://portal.genego.com/), 64% of all upregulated genes showed a possible 
regulation by NF-B (Fig. 7F, Supplementary Table S2). Analysis for binding sites for 
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AP-1 and Nrf2 revealed a putative regulation of 33% by Nrf2 and of 83% by AP-1 
with 30.6% of these genes showing overlapping regulation by Nrf2, AP-1 and NF-B 
(Supplementary Fig. S8). 
 Overall, our results demonstrate that the oxidative stress-dependent increase 
of several pro-metastatic genes is specifically regulated by NF-B and that this 
transcription factor might also play an important role in the upregulation of further 
pro-metastatic genes in IBC cells in response to CIH. 
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DISCUSSION 
Inflammatory breast cancer is the primary breast cancer form with the highest 
aggressiveness [2,3,66]. The underlying mechanisms are still unclear but are 
urgently needed to be deciphered in order to develop novel treatment options [5]. 
While a common feature of tumors, CIH is only beginning to be appreciated as an 
important regulator of cancer progression and metastases. CIH occurs when cancer 
cells outgrow the area of sufficient oxygen delivery and subsequent hypoxia-induced 
tumor angiogenesis leads to vessels with abnormal structures [8]. Such changes 
have also been demonstrated for IBC tumors [7,12]. CIH is a well-established source 
for oxidative stress, which can severely impact on gene expression, leading to 
increased cancer aggressiveness [19]. However, the relevance of CIH for IBC 
progression and metastases formation is unclear. In this study, we provide insights 
into the regulation of pro-metastatic gene expression through IH and oxidative stress 
in IBC cells, which appears to be mediated mainly by NF-B (Fig. 8). 
We identified that CIH leads to increased expression of ECM proteins in IBC 
cells, such as TNC, MMP2, MMP9 and ADAM19, and of proteins involved in 
inflammatory processes, such as COX-2. TNC, MMP2, MMP9 and COX-2 have 
previously been shown to highly promote breast cancer metastasis, and to be 
significantly stronger expressed in IBC tumors than in non-IBC breast cancer tumors 
[2,36,66,67]. Tumor inflammation has also been associated with cancer progression 
and metastasis formation and COX-2 was identified as a major component of the IBC 
molecular signature and suggested for targeted therapy for IBC [2,68]. Overall, these 
data demonstrate that CIH leads to the upregulation of pro-metastatic gene 
expression in IBC cells, which likely contributes to the aggressive phenotype of IBC. 
The transcriptional regulation of the TNC gene is complex and several 
different stimuli and transcription factors are involved [69]. TNC has previously been 
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shown to be regulated by AP-1, NF-B and Nrf2 [69-71], and although we observed a 
ROS-dependent activation of Nrf2, JNK and c-Jun, these factors did not regulate 
TNC in IBC cells. In our gene array, 33% of CIH-upregulated genes were identified to 
carry a putative Nrf2 binding sequence, but we did not observe any prototypical Nrf2 
target gene, such as HO-1 or other genes of the cellular antioxidant defense system 
[23]. Therefore, it seems unlikely that Nrf2 plays a major role in the here observed 
gene expression and no clear link between Nrf2 activity and IBC has been reported 
so far. 
The effect of oxidative stress on the HIF pathway is controversially discussed 
in the literature [8,18,19,24,25,27-29]. Here, in the CIH experiment, no HIF-1 
stabilization and no prototypical HIF-dependent gene expression pattern was 
observed. Following a stimulus such as hypoxia, HIF-1 reaches in most cells its 
highest protein levels after 6-8 h and declines subsequently due to negative feedback 
loops, even during a still continuing HIF-1 stabilizing stimulus [72-75]. Hence, it is 
not surprising that no HIF-1 protein levels and no HIF-dependent gene expression 
were detected in the CIH experiments, analyzing the samples 48 h following the end 
of the hypoxia period. These results indicate that the observed gene expression was 
not due to the initial hypoxic stimulus but rather due to the generated oxidative 
stress, and that this regulation is independent of HIF-1. 
The relevance of MAPK signaling and AP-1 activation in IBC is unclear, but 
overexpression of AP-1 subunits such as c-Jun and MAPK hyperactivation have 
been suggested [76,77]. While ROS-dependent TNC induction was independent of c-
Jun, 83% of the CIH-upregulated genes could potentially be regulated by AP-1. 
Therefore, a contribution of AP-1 to CIH-dependent gene regulation in IBC cells 
cannot be excluded but would need further investigations to determine its relevance. 
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We also observed oxidative stress-dependent activation of the NF-B 
signaling cascade at the level of or upstream of IB and TNC, MMP9 and COX-2 
were regulated by activation of the NF-B pathway. TNC has previously been 
suggested as a putative NF-B target gene in IBC [66,78], but although TNC is 
regulated by this transcription factor in other cell types, to our knowledge an NF-B-
dependent TNC regulation had not been shown in IBC cells before. Of note, chronic 
exposure of SUM149PT cells to IH did not change the ROS production in response 
to reoxygenation. This indicates that the observed gene regulation following CIH was 
either due to an increasing sensitivity of the IBC cells to ROS over the CIH time 
course, or that repeated ROS exposures were necessary to sufficiently activate NF-
B for the regulation of gene expression. 
The term “inflammatory breast cancer” could suggest an inflammation-driven 
cancer, but it originated from the clinical appearance of patients [4,79]. The role of 
inflammation in IBC aggressiveness is only beginning to be unraveled. Several 
studies indicated NF-B to be constitutively activated in IBC and to be a major 
contributor to IBC-specific gene expression and tumorigenesis [2,66,77,80]. As 
mechanisms for increased NF-B activity, infection with human cytomegalovirus 
(HCMV), loss of estrogen receptor (ER) and differential cytokine expression has 
been suggested [2]. In our study, we found that oxidative stress activates NF-B in 
IBC cells and that 64% of all CIH-upregulated genes can potentially be regulated or 
have been shown to be regulated by NF-B, such as COX-2 [81]. TNC, MMP9 and 
COX-2 gene induction by oxidative stress were directly linked to NF-B activation 
and increased TNC expression was associated with increased p105 expression in 
breast cancer tissue. Overall, these results demonstrate the importance of NF-B in 
pro-metastatic gene regulation in IBC cells in response to intermittent hypoxia. 
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Interestingly, TNC can activate toll-like receptor 4, which in turn activates NF-B, 
leading to a regulatory loop [78,82]. Furthermore, IH and inflammation can form a 
vicious circle in vivo, amplifying each other [83]. We therefore hypothesize that IH 
and oxidative stress play an important role in the constitutive activation of NF-B in 
IBC, which is facilitated through increased TNC expression. 
 In summary, CIH is a possible novel modulator of IBC aggressiveness, 
increasing pro-metastatic gene expression through activation of NF-B and maybe 
other transcription factors. Both CIH and NF-B should be further investigated as 
potential targets for therapy of inflammatory breast cancer. The impact of CIH should 
be considered in future studies of IBC tumor material, as CIH affects gene and 
protein expression and could lead to differences in expression levels between 
different biopsy sites. Taking into consideration the crosstalk between the tumor 
microenvironment and the cancer cells, such as between intermittent hypoxia and 
IBC cells, might allow us to develop novel approaches for IBC treatment. 
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FIGURE LEGENDS 
Fig. 1: Genes regulated by chronic intermittent hypoxia (CIH) in inflammatory 
breast cancer cells. (A) Experimental scheme of the CIH exposure regime, 
indicating the duration of exposure to hypoxia and normoxia, and the time points of 
sample collection. (B) Enrichment analysis of upregulated genes using MetaCore 
software to rank the most relevant cellular processes. 
 
Fig. 2: Gene array validation reveals three distinct groups of genes regulated 
by CIH. (A) Validation of gene array results for selected candidate genes in 
SUM149PT cells by RT-qPCR. (B) Heatmap showing the mRNA induction factors 
depicted in (A) following hypoxia, reoxygenation or CIH. (C) Immunoblot analysis of 
TNC protein levels in response to hypoxia, reoxygenation or CIH. (D) Quantification 
of TNC protein levels following hypoxia, reoxygenation or CIH. Hyp = hypoxia, Reox 
= reoxygenation; *, p<0.05; **, p<0.01; ***, p<0.001 (Student’s t-test). 
 
Fig. 3: Regulation of TNC gene expression by oxidative stress. DCF assays to 
quantify the generation of intracellular ROS levels by (A) reoxygenation (following 24 
h 0.2% O2), (B) 100 M H2O2 or (C) 30 M tBHQ over 4 h. RT-qPCR analysis of TNC 
mRNA induction in response to (D) reoxygenation (following 24 h 0.2% O2), (E) 100 
M H2O2 or (F) 30 M tBHQ over the indicated time course. TNC immunoblot 
analysis and quantification of relative protein levels in response to (G) reoxygenation 
(following 24 h 0.2% O2), (H) 100 M H2O2 or (I) 30 M tBHQ over the indicated time 
course. (J) Determination of secreted TNC protein levels in response to 30 M tBHQ 
over 24 hours by ELISA. Cell culture supernatants were used from samples of the 
experiment shown in Fig.4B. *, p<0.05; **, p<0.01; ***, p<0.001 (one-way ANOVA 
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followed by Tukey test for (D, G); Student’s t-test (J); two-way ANOVA followed by 
Bonferroni posttest for all other statistical analyses). 
 
Fig. 4: Effects of antioxidants on tBHQ-mediated TNC induction. (A) DCF 
analysis of tBHQ treatment (30 M) alone or following 1 h pre-treatment with 3 mM 
NAC. (B) Analysis and quantification of relative TNC protein levels in SUM149PT 
cells in response to 30 M tBHQ alone or following 1 h pre-treatment with 3 mM or 20 
mM NAC. Quantified values were normalized to -actin loading control and to the 
starting time point. n.s., not significant; **, p<0.01; ***, p<0.001 (Two-way ANOVA 
followed by Bonferroni posttest was applied for comparison of tBHQ treatment alone 
with the combinatorial treatment of tBHQ and NAC in (A); one-way ANOVA followed 
by Tukey test in (B)). 
 
Fig. 5: Role of Nrf2 and Nrf3 in oxidative stress-dependent TNC regulation. (A) 
UCSC-integrated ENCODE data proximal to the transcriptional start site of the TNC 
gene. The transcription factor ChIP-sequencing track shows regions of transcription 
factor binding derived from ChIP-seq experiments performed by the ENCODE 
project. The intensity of the grey shading is proportional to the signal strength 
observed in any cell line contributing to the respective cluster. Enrichment levels of 
histone marks (H3K4Me1, H3K4Me3, H3K27Ac) were determined by ChIP-seq and 
indicate regions of active enhancers (H3K4Me1, H3K27Ac) or active promoters 
(H3K4Me3). DNase hypersensitive areas reflect regulatory regions. Further relevant 
TFBS found in JASPAR and from published results were added in rectangles [71]. A 
circle shows relevant, additional TFBS found in the Swissregulon database. JUN, c-
Jun; ARE, antioxidant response element, targeted by Nrf2 and Nrf3. (B) Nrf2 or Nrf3 
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alone or Nrf2/Nrf3 in combination were knocked down for 48 h followed by treatment 
with 30 M tBHQ or solvent control (ethanol) for the indicated time points. TNC and 
(C) HO-1 mRNA levels were determined by RT-qPCR and normalized to 0 h siCtrl. 
(D) Cells were treated with 10 M SFN or solvent control (DMSO) and TNC and HO-
1 mRNA levels were determined by RT-qPCR. (E) TNC and HO-1 mRNA levels were 
determined by RT-qPCR following treatment with 40 M DMF or solvent control 
(DMSO). n.s., not significant; *, p<0.05; **, p<0.01; ***, p<0.001 (two-way ANOVA 
followed by Bonferroni posttest). 
 
Fig. 6: Role of JNK and c-Jun activity in oxidative stress-dependent TNC 
regulation. (A) Immunoblot analysis of total c-Jun and phosphorylated c-Jun protein 
after treatment with 30 M tBHQ or solvent control (ethanol) for the indicated time 
points. (B) SUM149PT cells were pre-treated for 1 h with different concentrations of 
the JNK inhibitor SP600125 (SP6) followed by a 9 h treatment with 30 M tBHQ or 
solvent control (ethanol). Total c-Jun and phosphorylated c-Jun protein was detected 
by immunoblotting. (C) Immunoblot analysis and quantification of relative TNC 
protein levels in response to 30 M tBHQ with or without 1 h pre-treatment with 
different concentrations of the JNK inhibitor SP600125 for the indicated time points. 
(D) Immunoblot analysis and quantification of relative of TNC protein levels after 
knockdown of c-Jun for 48 h and followed by treatment with 30 M tBHQ or solvent 
control (ethanol) for the indicated time points. n.s., not significant; **, p<0.01; ***, 
p<0.001 (one-way ANOVA followed by Tukey test). 
 
Fig. 7: Role of NF-B in oxidative stress-dependent TNC regulation. (A) 
Immunoblot analysis of IB protein levels following treatment with 30 M tBHQ or 
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solvent control (ethanol) for the indicated time points. (B) IB protein levels were 
analysed by immunoblotting following 1 h pre-treatment with different concentrations 
of the IB kinase (IKK) inhibitor BAY 11-7082 (BAY) and subsequent addition of 30 
M tBHQ or solvent control (ethanol) for 9 h. (C) SUM149PT cells were pretreated for 
1 h with 12.5 M BAY 11-7082 followed by 30 M tBHQ or solvent control (ethanol) 
for indicated time periods. TNC, MMP9 and COX-2 protein levels were analysed by 
immunoblotting and TNC levels were quantified. (D) Following transient 
overexpression of IBfor 24 h, cells were treated with 30 M tBHQ or solvent 
control (ethanol) for the indicated time periods and TNC, MMP9 and COX-2 protein 
levels were analyzed by immunoblotting. For the shown MMP9 immunoblot a 
previously cut membrane was used in an otherwise identical single experiment. (E) 
SUM149PT cells were treated with 2 ng/ml IL-1 or solvent control (0.1% BSA in 
PBS) for the indicated time course and IB TNC, MMP9 and COX-2 protein levels 
were analyzed by immunoblotting. (F) Analysis of NF-B binding sites in all CIH-
upregulated genes, observed in the gene array shown in Supplementary Table S1. 
The graph depicts the combined results of TFBS identification using the web-based 
software oPOSSUM and MetaCore. oPOSSUM and MetaCore identified TFBS 
profiles based on JASPAR and published results, respectively. n.s., not significant; 
***, p<0.001 (one-way ANOVA followed by Tukey test). 
 
Fig. 8: Proposed model of the molecular mechanisms by which intermittent 
hypoxia mediates pro-metastatic gene expression via activation of NF-B in 
inflammatory breast cancer cells. Intermittent hypoxia upregulates pro-metastatic 
genes in inflammatory breast cancer cells through activation of the transcription 
factor NF-B. 
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HIGHLIGHTS 
 Intermittent hypoxia (IH) increases pro-metastatic gene expression in IBC 
cells 
 ROS activates NF-B, Nrf2 and c-Jun in IBC cells 
 IH-dependent gene regulation depends on NF-B but not on other ROS-
induced pathways 
 IH is proposed as an important regulator of IBC aggressiveness 
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